Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy

24 May 2016

Abstract excerpt

Cancer immunotherapies are increasingly effective in the clinic, especially immune checkpoint blockade delivered to patients who have T cell-infiltrated tumors. Agonistic CD40 mAb promotes stromal degradation and, in combination with chemotherapy, drives T cell infiltration and de novo responses against tumors, rendering resistant tumors susceptible to current immunotherapies. Partnering anti-CD40 with different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Immunotherapy and Biomarkers
Share to Cancer, Stress, Anesthesia, and Immune Response

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27217585
DOI: 10.4049/jimmunol.1600146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after ChemotherapyPMID 27217585Read ↗

Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic modelSemantic proximity Read ↗

Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentSemantic proximity Read ↗

CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic TargetingSemantic proximity Read ↗

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read ↗

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read ↗

Prospect of Targeting the CD40 Pathway for Cancer TherapySemantic proximity Read ↗

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Semantic proximity Read ↗

A novel mouse model for checkpoint inhibitor-induced adverse events.Semantic proximity Read ↗

Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor controlSemantic proximity Read ↗

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSemantic proximity Read ↗

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunitySemantic proximity Read ↗

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.